Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep in mind if the BK goes through, this will wipe out all of the original investors that got IMGG to this point, even with the mismanagement investors have incurred.
In essence: Thanks for what you have done, have a nice life! If IMGG ever comes out of BK the new??? The new Investors will own the company and your shit out of luck if you were a previous investor.
Look at Delta Airlines. I hate to compare Delta Airlines to IMGG because Delta Airlines was/is real company to date,
but the outcome will be the same if the BK is approved. The previous SH will be holding a bag of shit!
I hate to be point blank, but It is called for in his instance!
The truth will be in the SEC filings soon.
If this is true from what MSU ADMIN stated, the share holders will see this commitment time and time again, in the numbers in the SEC filings???
This is a start, let’s sees if Mr. MSU ADMIN repeats the purchases over the next 12 months with the same volume or even increased Q over Q? Unfortunately this company needs to sell much more product than this to keep up with overhead cost, in reality.[/b
I guess the SH can wait another Q and be unimpressed once again! This has gone on for how Long?
The only thing that has ever moved the PPS in this company were the 2 Paid Promotions. I suspect we will have another one. The promoters need to change out the bag holders to continue to make this venture profitable.
"awareness campaign"
Are you thinking of anther Paid Promotion like the last time? Yes, this worked in the past and that is part of the problem.
Just what the company needs, more BAG HOLDERS.
Honestly I’m amazed this stock has not gone sub penny.
BP sells GAS, CONZ should fit right into the inventory.
Are there any Whole Foods, Sams Clubs, Costcos, BJs in NJ? Many Families are shopping in these locations since the economy went south. Oh, I forgot a major one Wal Mart?
I had lost track of time? Amazing its almost year later now.
I’m glad the investors finally get a slight glimpse of Mitch? Can anyone confirm this is Mitch Brown in the video?
$$makingit$$ you atated you had met Mitch Brown and the onsite FDA inspector in person from your previous post. Will you confirm this is Mitch Brown in the video, CEO of CNOZ?
This is a simple yes or no question. You may also use the default and opt not to answer. That’s understandable in your position.
V63
This is a reverse split no matter how they word it.
Simple math, the long term implications are a different matter.
We will see it in sales in the next Q report. Good or Bad, these are the real numbers.
adreamer
I assure you, BTH is up to date on Ariad.
BoD
NAVB
2nd Investor NDA Update
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-nda
2nd Investor NDA Update
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-nda
$$MAKING$IT$$
Thanks for being honest $$MAKING$IT$$, There is possibility that another organization is being utilized at this time?
This may or may not be on the company, but paid promotions occur on a regular basis in the Penny Stock realm. It has already occurred 2 times in the past with CNOS.
I expect anoher any day.
BoD
binchey'
My expectations are not that high,I was hoping for $20.00 by the end of 2012 and that has been exceeded. To keep it in context, I made this prediction in Aug 2011. That got me a free beer from a close friend and I purchased the next round.
I have all the info I need from ARIA for now. This will move higher.
All good things will come in time.
BoD
Some serious Tree Shaking going on today. We all know where this is headed in the long run!
Could there be another PRomotion on the way? THIS WOULD NOT NOT THE FIRST OR second time?
Do we have any online promoters at the board that would like to come forward?
ARIAD Presents Initial Clinical Proof-of-Concept of AP26113 in Patients with Non-Small Cell Lung Cancer at ESMO 2012 Congress
~ First evidence of clinical anti-tumor activity in patients resistant to ALK or EGFR inhibitor therapy~Investor conference call and webcast on Monday, October 1 at 8 a.m. ET
Published: September 29, 2012 Updated 1 hour ago
VIENNA & CAMBRIDGE, Mass. — ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The study provides compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose levels in patients with anaplastic lymphoma kinase positive (ALK+) NSCLC and initial clinical evidence of anti-tumor activity in patients with epidermal growth factor receptor mutant (EGFR-m) NSCLC. The results are being presented this morning at the ESMO 2012 Congress of the European Society for Medical Oncology being held in Vienna, Austria.
Patients enrolled in the trial have advanced solid tumors that were refractory to available therapies or had no standard or curative treatment available to them. The primary objectives of the Phase 1 portion of the trial are to determine the maximum tolerated dose (MTD) and the recommended dose for further study of AP26113 and to characterize its safety and preliminary anti-tumor activity. The trial uses an open-label, dose-escalating design. Anti-tumor activity was determined by serial CT scans using RECIST criteria.
Thirty-four patients have been enrolled to date in the study in six dose-cohorts (i.e., 30, 60, 90, 120, 180 and 240 mg administered orally once daily). Nineteen patients currently remain on study, with 16 at the three highest dose levels.
Twenty-nine of the patients enrolled to date in the study have NSCLC: 14 who are ALK+ and 11 who are EGFR-m. More than two-thirds of these patients failed three or more regimens of prior treatment, including both targeted therapies and chemotherapy.
“The initial findings from this ongoing study show that AP26113 has impressive anti-tumor activity in ALK+ NSCLC patients, who are either naïve or resistant to crizotinib,” stated Scott Gettinger, M.D., Associate Professor of Medicine at Yale School of Medicine, the study’s presenter at ESMO. “At the same time, it is encouraging to see a partial response in a patient with EGFR-mutant lung cancer and acquired resistance to erlotinib in the Phase 1 dose-escalation portion of the trial.”
Key data from the study presented at ESMO include:
Safety and Tolerability
• Safety data to date show AP26113 to be well tolerated. There was one patient with a dose-limiting toxicity (DLT) of elevated aspartate aminotransferase (ALT), a liver enzyme, observed at the 240 mg dose-level. The enzyme elevation resolved within eight days following drug interruption; the patient resumed therapy at a lower dose, remains on study and has achieved a partial response (PR). The 240 mg cohort has recently been expanded with the enrollment of three additional patients. The MTD has not yet been identified.
• The most common adverse events, all treatment emergent and across all grades, are nausea (32 percent) and fatigue (26 percent). The only treatment-related adverse events occurring in at least 10 percent of study patients are nausea (26 percent), diarrhea (18 percent), decreased appetite (12 percent), and vomiting (12 percent). There have been no signs of rash that would be considered typical of EGFR inhibitors at any doses studied.
Read more here: http://www.heraldonline.com/2012/09/29/4299711/ariad-presents-initial-clinical.html#storylink=cpy
ARIA
ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1739175&highlight=
ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 27, 2012-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA). ARIAD provided the FDA with remaining chemistry, manufacturing, and controls (CMC) data. ARIAD is seeking U.S. marketing approval of ponatinib in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The Company has requested accelerated approval and a priority review of the ponatinib application by the FDA.
“In late July, we submitted the NDA for ponatinib ahead of schedule and, at the request of the FDA, in advance of having the final CMC data. We look forward to continuing our progress towards making ponatinib available to patients with CML and Ph+ ALL,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “If approved, we believe that ponatinib will become an important new medicine for CML and Ph+ ALL patients who have become resistant or intolerant to prior tyrosine kinase inhibitor therapy.”
ARIAD anticipates approval and commercial launch of ponatinib in the U.S. in the first quarter of 2013. Also, the Marketing Authorization Application (MAA) for ponatinib, submitted in August, has been validated by the European Medicines Agency (EMA), commencing their review of the application. The Committee for Medicinal Products for Human Use (CHMP) has granted ARIAD’s request for accelerated assessment of the MAA.
I think this weekends news will be postive but nothing to run up the PPS much. I give it 55-45 odds.
All have a great weekend, nothing to worry about here.
BOD
Let me cut to the chase here! I read the PR from PPHM and have followed the company for a while now, No company releases a PR in that tone unless they think the trial is a total loss and the company may be in trouble. They have been honest with Share Holders in their statement. Its up to the Share Holders to do as they wish with their investment from that point on. The market will do what it does, but the company is covered because they have informed the Share Holders of the dire situation.
If you truly believe that PPHM has the goods, consider what a new Phase 2 trial will cost, the company’s debt, and I seriously doubt they will get a partner by time soon after this debacle?
Investor NDA Update
Navidea Provides Lymphoseek® NDA Update Statement
September 24, 2012
On September 10, 2012, Navidea announced that it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the new drug application (NDA) for Lymphoseek® (technetium Tc 99m tilmanocept) Injection. The CRL focused on current Good Manufacturing Practice (cGMP) deficiencies identified during inspections at third party manufacturer facilities and did not cite any Lymphoseek clinical efficacy and safety issues.
Over the last two weeks since receiving the CRL, the Company, as part of its continuing effort to secure regulatory NDA approval, has been working with FDA and the third-party manufacturers to develop a comprehensive response to the CRL. Navidea has scheduled a Type A meeting with the FDA in mid-October to advance the Company's planned CRL response. The Company will submit briefing materials to FDA for discussion in advance of the meeting to enable productive dialogue leading to the prompt resubmission of cGMP information and addressing the CRL response to the NDA.
The Company has been working closely with its manufacturing partners and consultants to address the requirements of the CRL, and remains encouraged by its discussions with FDA on the development and submission of an effective response to the CRL. The Company believes that the focused scope of the CRL, the nature of the cited deficiencies, and the already advanced level of completion of the corrective actions by the suppliers may facilitate a timely review of the CRL resubmission, which the Company anticipates will be classified as Class II, providing for FDA to act at any time from the resubmission date to up to six months from that date. The Company and its advising experts believe that the matters identified in the CRL concerning the cGMP deficiencies are readily addressable and are working to do so as quickly as possible. Gaining approval for Lymphoseek continues to be the priority of the Company as we work to develop our pipeline and grow Navidea into a leading precision diagnostics company.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements on this web page, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
PropThink: NAVB Up On Potential To Address Lymphoseek CRL Quickly
http://finance.yahoo.com/news/propthink-navb-potential-address-lymphoseek-192601687.html
First let me state you have no supporting documemtnts to support you statement of the previous post being a LIE?
Secondly, if the TF agent for CNOZ was un gagged. We would all know what the true OS standing share count is at..?????????? Do you know why this the way it is?
I have only one question for you now. Why would any up commining Company Such As CNOZ gag the Transfer Agent?
This makes no since unless one is attempting to hide something?
Panther 41
Please give us your words on this. You seem to post often, and attempt to lead this board.
The Board is awaiting your reply? Honestly I think the SH would prefer to here from Mihch? Brown
Panther41 Please explain your comment of calling that post a lie? I must have missed some or your DD.
THE FINAL CHAPTER
IMHO the Bankruptcy will eventually be approved. What will be interesting is, what the FEDS will find while SCRUTIZINIZING IMGG’s books, proxy votes,the six S3 filings, and the loan shark deals during this process.
This will probably have an impact on some peoples future.
Posted by 42Delta
NAVB latest short interest report as of 8/31
http://www.nasdaq.com/symbol/navb/short-interest
new money likes bargains
Before the end of the year 22.70 will look like a real bargain imho
I don't think He will be moving anywhere, any time soon! But those were very nice photos.
I have a few on my list that I would like photos of, in this same studio.
BOD
Is this an appeal? Usually convictions are very diffcult to overturn.
Believe it or not? It still happens today!
I like the photos! That must be the only photo that was ever taken with his mouth closed?
Imagine that.
Followed By 77
Posts 87
He had the gift of gab. His followers to post ratio is, Opps was unreal?
To our CEOs at the Cnoz board.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79502662
P41
Web pages are not hard to create. Just look at the intro for CONS board. It was obviously done by an amateur, but at least it has some information.
In my opinion, a web page represents a company’s image to the public especially since the internet has grown over the years. The net is the business model for some of the top company’s in the world. I don’t think I have to name them? You probably use one of them every day.
I think many here would agree, both bears and bulls.
Any members wishing to listen to the recent Conference call from Navidea here is the information.
Thank you Trade2much for providing this.
Call 1-877-660-6853
Account #286
Conf # 400026
Good luck and I hope it helps out
No news from NAVB yet. Here is a link to Navidea for quick reference.
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-news&nyo=0
NAVB receives CRL
Conference Call Scheduled for 4:45 p.m. ET September 10, 2012
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection. In the CRL, the FDA noted the decision was focused on issues with third-party Lymphoseek contract manufacturing, and was not related to any efficacy or safety data filed within the Lymphoseek NDA.
Lymphoseek is a novel agent that has been studied in lymphatic mapping procedures performed to help stage breast cancer and melanoma. Lymphoseek is a receptor-targeted radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.
"Receiving a Complete Response Letter is clearly disappointing. However, we remain steadfast in our belief that Lymphoseek holds significant promise in improving the lives of patients who undergo lymphatic mapping procedures to stage solid tumor cancers, such as breast cancer and melanoma," said Mark Pykett, V.M.D, Ph.D., President and CEO of Navidea Biopharmaceuticals. "We are already working closely with the FDA and our third-party contract manufacturers to address all requirements to support the shortest possible NDA resubmission and review. We remain confident that our clinical data clearly demonstrate the value of Lymphoseek in accurately identifying lymph nodes that most likely harbor cancer while producing no clinically significant adverse effects," Pykett added.
Navidea Biopharmaceuticals will provide additional information during a conference call scheduled for 4:45 p.m. EST, September 10, 2012. The conference call can be accessed as follows:
Trading aside
I would love to see it approved after hours today, and LET THE SHORTS SUFFER ALL WEEKEND!